ATE520420T1 - Das telomelysin-gfp-gen enthaltendes rekombinantes virus - Google Patents

Das telomelysin-gfp-gen enthaltendes rekombinantes virus

Info

Publication number
ATE520420T1
ATE520420T1 AT05790164T AT05790164T ATE520420T1 AT E520420 T1 ATE520420 T1 AT E520420T1 AT 05790164 T AT05790164 T AT 05790164T AT 05790164 T AT05790164 T AT 05790164T AT E520420 T1 ATE520420 T1 AT E520420T1
Authority
AT
Austria
Prior art keywords
adenovirus
telomelysin
gene
recombinant virus
gfp gene
Prior art date
Application number
AT05790164T
Other languages
English (en)
Inventor
Toshiyoshi Fujiwara
Noriaki Tanaka
Satoru Kyo
Hiroyuki Mizuguchi
Takao Hayakawa
Original Assignee
Oncolys Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolys Biopharma Inc filed Critical Oncolys Biopharma Inc
Application granted granted Critical
Publication of ATE520420T1 publication Critical patent/ATE520420T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0045—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent agent being a peptide or protein used for imaging or diagnosis in vivo
    • A61K49/0047—Green fluorescent protein [GFP]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
AT05790164T 2004-09-29 2005-09-28 Das telomelysin-gfp-gen enthaltendes rekombinantes virus ATE520420T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004285383 2004-09-29
PCT/JP2005/018401 WO2006036004A1 (ja) 2004-09-29 2005-09-28 テロメライシン-gfp遺伝子含有組換えウイルス

Publications (1)

Publication Number Publication Date
ATE520420T1 true ATE520420T1 (de) 2011-09-15

Family

ID=36099363

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05790164T ATE520420T1 (de) 2004-09-29 2005-09-28 Das telomelysin-gfp-gen enthaltendes rekombinantes virus

Country Status (15)

Country Link
US (3) US7943373B2 (de)
EP (2) EP1795604B1 (de)
JP (1) JP5006045B2 (de)
KR (1) KR20070059191A (de)
CN (1) CN101035906A (de)
AT (1) ATE520420T1 (de)
AU (1) AU2005288034A1 (de)
BR (1) BRPI0516191A (de)
CA (1) CA2581969A1 (de)
EA (1) EA011880B1 (de)
IL (1) IL181876A0 (de)
MX (1) MX2007002999A (de)
NZ (1) NZ554799A (de)
WO (1) WO2006036004A1 (de)
ZA (1) ZA200703294B (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192208B2 (en) 2003-09-02 2007-03-20 Futurelogic, Inc. Rewritable card printer
US8057296B2 (en) * 2003-09-12 2011-11-15 Igt Gaming device including a card processing assembly having vertically-stacked card holders operable with thermally-printable data cards and portable card changeover machines
US20080153581A1 (en) * 2003-09-12 2008-06-26 Igt Card loading system for a data card unit
US7494414B2 (en) 2003-09-12 2009-02-24 Igt Gaming device having a card management system for the management of circulating data cards
US20080153580A1 (en) * 2003-09-12 2008-06-26 Igt Bezel interface for a card loading system
JP5069871B2 (ja) * 2006-05-30 2012-11-07 シスメックス株式会社 新規な癌細胞検出試料調製用キット及びそれを用いた癌細胞検出用キット
JP5010890B2 (ja) * 2006-10-11 2012-08-29 オリンパス株式会社 生体試料解析方法
US8197334B2 (en) 2007-10-29 2012-06-12 Igt Circulating data card apparatus and management system
US20090181931A1 (en) * 2008-01-16 2009-07-16 Oncolys Biopharma, Inc. Antiviral activity of cidofovir against oncolytic viruses
US20110065117A1 (en) * 2008-04-11 2011-03-17 National University Corporation Okayama University Mesothelioma Specific Transferred Promoter And Use Thereof
JPWO2010071114A1 (ja) * 2008-12-18 2012-05-31 シスメックス株式会社 血液試料中の癌細胞の検出方法
CN101538556B (zh) * 2009-01-07 2011-09-21 四川大学华西第二医院 腺病毒选择性互补复制的方法
US9624476B2 (en) 2011-08-23 2017-04-18 National Institute Of Biomedical Innovation Conditionally replicating adenovirus
EP2749647B1 (de) * 2011-08-23 2018-07-04 National Institute of Biomedical Innovation Bedingt replikationskompetentes adenovirus
CA2865642C (en) * 2012-03-14 2021-10-26 Salk Institute For Biological Studies Adenoviral tumor diagnostics
CN103088061B (zh) * 2013-01-15 2016-08-03 中国科学院微生物研究所 一种rna及载体在制备预防和/或治疗肝癌产品中的应用
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
JP5812361B2 (ja) * 2013-07-11 2015-11-11 国立研究開発法人医薬基盤・健康・栄養研究所 遺伝子発現制御機構を含む新規Ａｄベクター
ES2899913T3 (es) 2014-09-24 2022-03-15 Salk Inst For Biological Studi Virus tumorales oncolíticos y métodos de uso
WO2016057387A1 (en) * 2014-10-06 2016-04-14 The Trustees Of The University Of Pennsylvania Compositions and methods for isolation of circulating tumor cells (ctc)
DE102015111756A1 (de) 2015-07-20 2017-01-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Rekombinanter Orf-Virus-Vektor
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
EP3390645B1 (de) 2016-02-23 2022-09-14 Salk Institute for Biological Studies Exogene genexpression eines therapeutischen adenovirus mit geringem einfluss auf die virale kinetik
AU2017375633C1 (en) 2016-12-12 2023-04-27 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
BR112020019942A2 (pt) 2018-04-09 2021-01-26 Salk Institute For Biological Studies composições de adenovírus oncolítico com propriedades de replicação aprimoradas
KR102080996B1 (ko) * 2018-07-23 2020-02-25 주식회사 코어파마 암세포 특이적 아데노바이러스
JPWO2021010369A1 (de) * 2019-07-12 2021-01-21
CN113444730A (zh) * 2021-03-17 2021-09-28 昆明市延安医院 一种原发性肝细胞klotho基因转导干细胞筛选构建方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036650A2 (en) * 1999-11-15 2001-05-25 Onyx Pharmaceuticals, Inc. An oncolytic adenovirus
WO2002012524A2 (en) * 2000-08-03 2002-02-14 Onyx Pharmaceuticals, Inc. Adenovirus e1b-55k single amino acid mutants and methods of use
JP2004536607A (ja) * 2001-07-23 2004-12-09 オニックス ファーマシューティカルズ，インコーポレイティド 標的化されたヒト癌細胞において選択的に複製するウイルス変異体
JP3867968B2 (ja) 2002-07-08 2007-01-17 関西ティー・エル・オー株式会社 腫瘍細胞において選択的に増殖する腫瘍融解ウイルス
JP3752544B2 (ja) 2003-02-03 2006-03-08 国立大学法人 長崎大学 細胞死誘発遺伝子を含有するベクターおよび医薬組成物

Also Published As

Publication number Publication date
IL181876A0 (en) 2007-07-04
WO2006036004A1 (ja) 2006-04-06
US20080032283A1 (en) 2008-02-07
NZ554799A (en) 2009-03-31
US20060067890A1 (en) 2006-03-30
KR20070059191A (ko) 2007-06-11
EP1795604A1 (de) 2007-06-13
EP1795604B1 (de) 2011-08-17
ZA200703294B (en) 2008-08-27
US20110111480A1 (en) 2011-05-12
AU2005288034A1 (en) 2006-04-06
JPWO2006036004A1 (ja) 2008-05-15
MX2007002999A (es) 2007-08-07
BRPI0516191A (pt) 2008-08-26
EP2311499A1 (de) 2011-04-20
US7943373B2 (en) 2011-05-17
CA2581969A1 (en) 2006-04-06
EP1795604A4 (de) 2008-08-27
EA200700694A1 (ru) 2007-08-31
CN101035906A (zh) 2007-09-12
EP2311499B1 (de) 2012-08-29
EA011880B1 (ru) 2009-06-30
JP5006045B2 (ja) 2012-08-22

Similar Documents

Publication Publication Date Title
ZA200703294B (en) Telomelysin-GFPgene-containing recombinant virus
Kirn et al. ONYX-015: clinical data are encouraging
Haviv et al. Conditional gene targeting for cancer gene therapy
JP2025160281A (ja) 個別化ワクチン
DE602005021509D1 (de) Modifizierte vitamin-k-abhängige polypeptide
PE20060277A1 (es) Adenovirus quimericos en el tratamiento del cancer
Marcellus et al. Expression of p53 in Saos-2 osteosarcoma cells induces apoptosis which can be inhibited by Bcl-2 or the adenovirus E1B-55 kDa protein.
WO2007070392A3 (en) Adenoviral expression vectors having an expression cassette in the e1 region and an inactivated e2b polymerase
PT797676E (pt) Vector adenoviral recombinante e metodos de utilizacao
ATE246252T1 (de) Von adenovirus abgeleitete rekombinante vektoren, für gentherapie
Seemann et al. The tumor suppressor gene TP53: implications for cancer management and therapy
Stamatiou et al. Investigation of BK virus, Epstein-Barr virus and human papillomavirus sequences in postoperative thyroid gland specimens
WO2003099859A3 (de) Neue verwendung von adenoviren und dafür codierenden nukleinsäuren
Kwak et al. Hepatitis C virus core activates proteasomal activator 28γ expression via upregulation of p53 levels to control virus propagation
Chen et al. Antitumor potential of SLPI promoter controlled recombinant caspase-3 expression in laryngeal carcinoma
Uch et al. Hepatoma cell-specific ganciclovir-mediated toxicity of a lentivirally transduced HSV-TkEGFP fusion protein gene placed under the control of rat alpha-fetoprotein gene regulatory sequences
Hu et al. Both core and F proteins of hepatitis C virus could enhance cell proliferation in transgenic mice
Lamas et al. Localization of insulin-like growth factor-II and hepatitis B virus mRNAs and proteins in human hepatocellular carcinomas.
ATE275200T1 (de) Genabgabe-vehikel die das apoptosis vp2 inducierendes protein, und/oder apoptin exprimiert
Jeong et al. HBx natural variants containing Ser-101 instead of Pro-101 evade ubiquitin-dependent proteasomal degradation by activating proteasomal activator 28 gamma expression
Jin et al. Cell-specific expression of the analgesic-antitumor peptide coding sequence under the control of the human α-fetoprotein gene promoter and enhancer
Xu et al. A novel transcript variant of proteasome activator 28γ: Identification and function in oral cancer cells
Yang et al. SCYL1BP1 has tumor-suppressive functions in human lung squamous carcinoma cells by regulating degradation of MDM2
Xue et al. Adenovirus vector expressing mda-7 selectively kills hepatocellular carcinoma cell line Hep3B.
Davies et al. Synthesis of Sendai virus polypeptides by a cell-free extract from wheat germ

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties